Lille (France), Cambridge (Massachusetts, United States), July 3, 2008 – Today, Xavier Guille des Buttes was elected Chairman of the Supervisory Board of GENFIT (Alternext: ALGFT; ISIN: FR0004163111) of which he has been the temporary Chairman until today.
As expected, the Company today also announced the appointments of two new members to reinforce the Management Board chaired by President Jean-François Mouney: Raphael Darteil, Senior VP, Scientific Operations and Nathalie Huitorel, VP Finance.
Biographies
Xavier Guille des Buttes, 66, is a member of the Supervisory Boards of DIAGAST and FINANCIÈRE DELPHARM. In the course of the last thirty years with SCHERING SA, Xavier Guille des Buttes has held a number of functions, particularly Marketing Director, Managing Director of the Pharmaceutical Division and Chairman of the Management Board until June 2006. He is a graduate of the ESSCA University of Angers, the International Commerce Institute (ICI) and the Forecast Management and Controlling Institute (ICG). Xavier Guille des Buttes is Chevalier of the Legion of Honor.
Raphaël Darteil, 43, earned a PhD in molecular and cellular biology from Université Claude Bernard (Lyon I). He has held a number of positions within the Department of Genic Therapy of Aventis Gencell both in France and in the U.S. He has above all been supervising the implementation and coordination of GENFIT’s industrial alliances from 2001. Since 2007, he is Senior Vice President, Director of Scientific Operations.
Nathalie Huitorel, 46, a graduate of ESC Lille, School of Management, has been, for the past 10 years, CFO for MS COMPOSITES, a leader specializing in high-performance materials. Previously, she took part in listing the French company FINUCHEM on the Stock Exchange and has led numerous mergers and acquisitions. Ms. Huitorel was appointed GENFIT’s VP Finance in December 2007.
About GENFIT
A biopharmaceutical company, GENFIT studies the deregulation of genes implicated in many of the most widespread diseases. GENFIT’s scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT’s programs, conducted in partnership with pharmaceutical companies such as SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG, and SERVIER, treat the most prevalent metabolic and inflammatory diseases. GENFIT’s development of proprietary drugs focuses on global cardiovascular risk factors, using a single molecule to simultaneously attack several pathologies (atherosclerosis, diabetes, obesity, etc.). GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development – development carried out by GENFIT alone or in partnership. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111).
(www.genfit.com).
Contacts :
GENFIT
Jean-François Mouney – CEO, Chairman of the Management Board
+ 33 (0)3 20 16 40 00
MILESTONES – Relation Presse
Bruno Arabian
01 75 44 87 40 / 06 87 88 47 26 - milestones@milestones-fr.com
